{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T17:06:06Z","timestamp":1779815166679,"version":"3.53.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019914","name":"Flatiron Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.urology.2026.01.024","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T17:25:17Z","timestamp":1769707517000},"page":"43-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer"],"prefix":"10.1016","volume":"211","author":[{"given":"Mehmet A.","family":"Bilen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabree","family":"Burbage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Khilfeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lowentritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2026.01.024_bib1","unstructured":"American Cancer Society. Key Statistics for Prostate Cancer. \u3008https:\/\/www.cancer.org\/cancer\/prostate-cancer\/about\/key-statistics.html\u3009. Accessed November 28, 2024."},{"key":"10.1016\/j.urology.2026.01.024_bib2","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results. Cancer Stat Facts: Prostate Cancer. \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html\u3009. Accessed November 28, 2024."},{"key":"10.1016\/j.urology.2026.01.024_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae183","article-title":"Treatment patterns for patients with BRCA1\/2-positive metastatic castration-resistant prostate cancer","volume":"30","author":"Bilen","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.urology.2026.01.024_bib4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2026.01.024_bib5","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1007\/s12325-025-03270-z","article-title":"Comparison of real-world outcomes between patients with BRCA1\/2-positive and homologous recombination repair-negative metastatic castration-sensitive prostate cancer","volume":"42","author":"Bilen","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.urology.2026.01.024_bib6","first-page":"5094","article-title":"Impact of somatic\/germline homologous recombination repair (HRR) alterations on metastatic hormone-sensitive prostate cancer (mHSPC) outcomes by disease volume","volume":"43","author":"Olmos","year":"2025","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.urology.2026.01.024_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/life14020198","article-title":"PARP inhibitors in metastatic castration-resistant prostate cancer: unraveling the therapeutic landscape","volume":"14","author":"Al-Akhras","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.urology.2026.01.024_bib8","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2026.01.024_bib9","article-title":"Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes","volume":"43","author":"Attard","year":"2025","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.urology.2026.01.024_bib10","first-page":"748","article-title":"Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline","volume":"43","author":"Yu","year":"2025","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.urology.2026.01.024_bib11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2217\/fon-2021-1113","article-title":"Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan","volume":"18","author":"Leith","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.urology.2026.01.024_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.23186","article-title":"Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers","volume":"7","author":"Hage Chehade","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urology.2026.01.024_bib13","article-title":"Clinical actionability and utilization of next-generation sequencing for prostate cancer in a changing treatment landscape","volume":"2","author":"Griffin","year":"2022","journal-title":"Front\u00a0Urol"},{"key":"10.1016\/j.urology.2026.01.024_bib14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41391-024-00815-1","article-title":"Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer","volume":"27","author":"George","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2026.01.024_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34208","article-title":"Biomarker-directed therapy in Black and White men with metastatic castration-resistant prostate cancer","volume":"6","author":"Hwang","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urology.2026.01.024_bib16","article-title":"Racial disparity in the genomics of precision oncology of prostate cancer","volume":"6 1","author":"Le","year":"2023","journal-title":"Cancer Rep"},{"key":"10.1016\/j.urology.2026.01.024_bib17","unstructured":"Birnbaum B., Nussbaum N., Seidl-Rathkopf K., et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. In:2020:arXiv:2001.09765."},{"key":"10.1016\/j.urology.2026.01.024_bib18","doi-asserted-by":"crossref","unstructured":"Ma X., Long L., Moon S., et al Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. 2023:2020.2003.2016.20037143.","DOI":"10.1101\/2020.03.16.20037143"},{"key":"10.1016\/j.urology.2026.01.024_bib19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1377\/hlthaff.2017.1579","article-title":"Real-world evidence in support of precision medicine: clinico-genomic cancer data as a case study","volume":"37","author":"Agarwala","year":"2018","journal-title":"Health Aff"},{"key":"10.1016\/j.urology.2026.01.024_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12885-020-07714-3","article-title":"Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States","volume":"21","author":"Hess","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urology.2026.01.024_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.urology.2026.01.024_bib22","article-title":"PD13-10: real-world time-to-next-treatment and time-to-castration-resistance among patients with metastatic castration-sensitive prostate cancer using androgen-receptor pathway inhibitors with and without homologous recombination repair alterations","volume":"213","author":"Lin","year":"2025","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2026.01.024_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.euo.2023.07.008","article-title":"Efficacy of National Comprehensive Cancer Network guidelines in identifying pathogenic germline variants among unselected patients with prostate cancer: the PROCLAIM trial","volume":"6","author":"Shore","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urology.2026.01.024_bib24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2024.0851","article-title":"Genetic testing in men with metastatic castration-resistant prostate cancer","volume":"10","author":"Barata","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2026.01.024_bib25","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2767-9764.CRC-24-0134","article-title":"Association of race and ethnicity with genomic testing at a comprehensive cancer center in North Carolina","volume":"4","author":"Meernik","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.urology.2026.01.024_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamaoncol.2023.4513","article-title":"Assessment of changes in cancer treatment during the first year of the COVID-19 pandemic in the US","volume":"10","author":"Nogueira","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2026.01.024_bib27","unstructured":"Association for Molecular Pathology. Molecular Testing for Cancer during COVID-19. 2021."},{"key":"10.1016\/j.urology.2026.01.024_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110257","article-title":"Advancing health equity in the aftermath of COVID-19: confronting intensifying racial disparities","volume":"27","author":"Prentice","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.urology.2026.01.024_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.26546","article-title":"Race and treatment outcomes in patients with metastatic castration-sensitive prostate cancer: a\u00a0secondary analysis of the SWOG 1216 phase 3 trial","volume":"6","author":"Sayegh","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urology.2026.01.024_bib30","first-page":"1467","article-title":"Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non-small cell lung cancer","volume":"30","author":"Bestvina","year":"2024","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526000609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526000609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:43:10Z","timestamp":1779813790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429526000609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"alternative-id":["S0090429526000609"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2026.01.024","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2026.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}